Melanotan 2 (MT2) (20mg)

• 1 x 10ml sterile multi-dose vial
• Active ingredient: Melanotan II at 2mg/ml
• Reconstituted in bacteriostatic saline
• Clear injectable solution
• For subcutaneous injection only

Melanotan II is a synthetic analog of the alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide that activates melanocortin receptors in the body. It was originally developed for its melanogenesis-stimulating effects, increasing skin pigmentation without UV exposure.

Melanotan II also shows activity at the MC3R and MC4R receptors, contributing to increased libido, erection enhancement, and appetite suppression in some individuals.

It is commonly used for:

• Skin tanning without sun exposure
• Sexual function enhancement (especially in men with ED or low libido)
• Photoprotection for fair-skinned individuals prone to sunburn

Melanotan II mimics alpha-MSH, a peptide hormone that binds to melanocortin receptors (MC1R–MC5R).

Primary effects include:

• MC1R activation: Stimulates melanin production in melanocytes, increasing skin pigmentation
• MC3R/MC4R activation: Stimulates sexual arousal centers in the brain, increasing libido and erectile function
• Secondary effects: Appetite suppression, enhanced mood, improved photoprotection

Unlike UV-dependent tanning, Melanotan II stimulates pigmentation from within, offering protection from UV damage and reducing sunburn risk in fair-skinned individuals.

Melanotan II is generally well tolerated when dosed conservatively, but side effects are more common at higher doses.

Potential side effects may include:

• Facial flushing or warmth
• Mild nausea (especially at start of therapy)
• Headache or dizziness
• Yawning or fatigue
• Increased libido and spontaneous erections (males)
• Injection site redness or bruising
• Darkening of moles and freckles (reversible)

Side effects usually resolve as tolerance builds. Taking with food and injecting in the evening may help reduce nausea and fatigue.

Potential Benefits:

• Safe, gradual skin tanning without excessive UV exposure
• May reduce sunburn risk through increased melanin
• Libido and erectile function support in men
• Appetite suppression (reported in some users)
• Potential photoprotection in individuals with light skin or photosensitivity

⚠️ Possible Side Effects:

• Nausea, flushing, or yawning
• Injection site irritation
• Spontaneous erections (males)
• Temporary darkening of existing moles/freckles
• Rare: anxiety or lightheadedness

Side effects are typically transient and dose-dependent. Most users tolerate 250–500 mcg well.

• Not recommended in individuals with skin cancers (e.g., melanoma) or familial mole syndromes
• Avoid use in individuals with uncontrolled hypertension or cardiovascular disease
• Use with caution in individuals prone to nausea or hypotension
• Should not be used continuously for long periods without periodic breaks
• Regular skin exams are advised during use

There are no significant drug-drug interactions reported with Melanotan II. However, caution is advised when used with:

• CNS stimulants or depressants (may enhance side effects)
• PDE5 inhibitors (may amplify sexual function effects)
• Immunosuppressants (rare theoretical interaction via MC receptors)

Melanotan II may enhance effects of libido-enhancing agents and may suppress appetite alongside weight management compounds.

Melanotan II has not been studied in pregnant or breastfeeding individuals and should not be used during these periods. Its effects on fetal development and hormone regulation are unknown.

Melanotan II is not approved for pediatric use and should not be used in individuals under the age of 18. This compound is designed for adult use only, with a focus on pigmentation, sexual function, and sun sensitivity in mature populations.

Melanotan II is not FDA-approved for medical use. It is classified as an investigational compound. While it has been studied for erectile dysfunction, sexual dysfunction, and tanning, no commercial product has received full regulatory approval in the U.S.

1. Hadley ME, et al. (2006). “Melanocortin peptides: role in skin pigmentation and sexual behavior.” Peptides.
2. Wessells H, et al. (2000). “Effect of Melanotan II on sexual arousal in men.” Journal of Urology.
3. Levine N, et al. (2003). “Melanotan II as a potential tanning agent.” Annals of the NY Academy of Sciences.
4. Eisenegger C, et al. (2015). “Neurobiological effects of melanocortin receptor agonists.” Frontiers in Neuroscience.
5. FDA.gov – Drug Approval Reports & Investigational Peptides